OUTLOOK THERAPEUTICS, INC. (OTLK) Profit Breakdown
- 2026-06-30: Development and Commercialization Of Ons-5010 Or Lytenava -$8.27K.
- 2025-06-30: Development and Commercialization Of Ons-5010 Or Lytenava $1.07M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2015-03-31 to 2026-06-30
- Data captured
Profit by product
Gross profit: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | -$8.27K |
|---|
| 2025-06-30 | $1.07M |
|---|
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | -$20.32M |
|---|
| 2025-06-30 | -$20.15M |
|---|
Operating income: each quarter (3 month)
| Quarter end | Development and Commercialization Of Ons-5010 Or Lytenava |
|---|
| 2026-06-30 | -$10.81M |
|---|
| 2025-06-30 | -$15.75M |
|---|